SB3522 (No Red Tape For Addiction Treatment Act) amends title XIX of the Social Security Act to force State Medicaid programs to cover at least one formulation of every drug and biological product listed for treatment of opioid use disorder without using prior authorization or conditioning payment on limits to dosage. The bill also directs MACPAC to report to Congress on how States use utilization management for medication‑assisted treatment (MAT) and what administrative barriers clinicians face.
This is a targeted federal intervention: it removes two common gatekeeping tools—prior authorization and dosage limits—for at least one formulation of each OUD medication type and sets a one‑year effective timeline (with a narrow State‑legislation exception). For payers, providers, and state Medicaid officials, the change rebalances access and cost control and will force operational changes in formularies, managed care contracts, and prescribing workflows.
At a Glance
What It Does
Adds a new paragraph to section 1905 requiring State Medicaid plans (and waivers) to cover at least one formulation of each drug/biologic used for opioid use disorder treatment without prior authorization or conditioning coverage on dosage limits; where available, a long‑acting injectable formulation should be among covered options. It also amends 1927(d)(1)(A) to carve out this requirement from the usual formulary language.
Who It Affects
Directly affects State Medicaid agencies, Medicaid managed care organizations, pharmacies and dispensing entities, clinicians who prescribe MAT, manufacturers of OUD medications (including long‑acting injectables), and Medicaid enrollees with opioid use disorder. CMS will need to interpret and enforce the new requirement.
Why It Matters
By eliminating prior authorization and dosage caps for at least one formulation per medication type, the bill removes common administrative barriers that slow or block access to evidence‑based treatment, while raising immediate fiscal and implementation questions for state programs and managed care plans. The required MACPAC report will supply Congress with a cross‑state snapshot of utilization controls to inform future policy.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a new requirement in Medicaid law that forces State plans to provide coverage, without prior authorization or coverage‑contingent dosage limits, for at least one formulation of each drug or biological product used to treat opioid use disorder. Where a long‑acting or injectable formulation exists for a covered product, the statute expressly anticipates including such a formulation among the options a State must cover without those utilization controls.
The text ties this obligation to the list of drugs referenced in existing subsection 1905(ee)(1)(A), so the statutory obligation applies to the categories the statute already recognizes.
Practically, states cannot require prior authorization or make payment contingent on a dosage cap for the designated formulation(s). That does not mean every formulation of every product becomes freely available—states retain the ability to set formularies consistent with other statutory provisions—but they must guarantee at least one unrestricted option per medication type.
The bill includes a conforming change to section 1927(d)(1)(A) to reflect that exception in the formulary rules.The effective date is set for medical assistance provided on or after one year after enactment, but the bill gives states additional time if complying requires state legislation: a State gets until the first calendar quarter after the close of the first legislative session that starts after enactment (with a two‑year session counted year‑by‑year). Finally, the bill orders MACPAC to deliver a report within one year describing how States use utilization management for MAT—looking at dosing caps, age limits, counseling and screening requirements—and to assess administrative burdens and other Medicaid policies that impede access.Taken together, the statutory change imposes a federal minimum on utilization management for MAT while leaving room for states to control access through other legal, clinical, or formulary tools.
The MACPAC report is structured to produce empirical context about how States currently deploy controls and where administrative frictions arise.
The Five Things You Need to Know
The bill requires State Medicaid plans (and waivers) to cover at least one formulation of every drug or biological product described in 1905(ee)(1)(A) for opioid use disorder treatment without prior authorization or conditioning coverage on dosage limits.
If a long‑acting injectable formulation exists for a covered drug/biologic, the State must include at least one such formulation among the options it provides without prior authorization.
The bill adds a conforming amendment to section 1927(d)(1)(A) to carve this requirement out of the general formulary language, preserving other formulary mechanics while imposing this federal floor.
The rule takes effect for medical assistance furnished one year after enactment, but States that need to change their laws get an extension until the first calendar quarter after the close of their next legislative session (two‑year sessions treated annually).
MACPAC must report to Congress within one year on utilization management for MAT across all States, including dosing restrictions, age limits, counseling and screening requirements, the administrative burden on providers, and other Medicaid policies that impede access.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the Act’s name: No Red Tape For Addiction Treatment Act. Short titles are informational, but the choice signals the bill’s policy aim—reducing administrative barriers to addiction treatment—which matters for how agencies prioritize guidance and enforcement.
Mandate that at least one formulation per medication type be PA‑free and uncapped
This is the substantive change: the bill inserts paragraph (4) in 1905(ee) requiring State plans and waivers to cover at least one formulation of each drug or biological product listed in the statute without prior authorization or conditioning coverage/payment on dosage limits. The provision anticipates long‑acting injectable formulations by reference — if such a formulation exists, it should be among available PA‑free options. Operationally, States must identify which formulation satisfies the requirement and ensure payment systems and MCO contracts permit access without PA or payment‑based dosage limits.
Carve‑out in drug formulary statute
The bill amends the formulary provision at 1927(d)(1)(A) to insert an explicit exception: except as provided in new 1905(ee)(4), a State may continue to use formulary rules. In practice, the amendment limits a State’s formulary flexibility only to the extent the new paragraph guarantees a PA‑free, uncapped option for each medication type; States retain other formulary controls consistent with 1927(d)(4). Expect legal questions about how broadly CMS interprets that interplay when it issues guidance.
One‑year effective date with a legislative compliance window
The statute applies to assistance furnished on or after one year from enactment. However, if a State must change its laws to comply, the bill prevents penalizing the State for noncompliance until the first calendar quarter after the close of the first regular legislative session that begins after enactment (in two‑year sessions, each year counts separately). This clause reduces immediate exposure for States that need legislative action, but it creates staggered implementation timetables across jurisdictions and operational complexity for CMS oversight.
MACPAC report on utilization management
The bill requires the Medicaid and CHIP Payment and Access Commission to submit a report within one year analyzing how States use utilization management for MAT—dosing restrictions, age limits, counseling and screening requirements—assessing administrative burdens on clinicians, and identifying other Medicaid policies that impede access. Lawmakers will get an empirical cross‑state snapshot intended to inform future adjustments; however, the report’s utility will depend on MACPAC’s access to granular claims, MCO, and policy data.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicaid enrollees with opioid use disorder — gain faster, more reliable access to at least one covered formulation without administrative delays tied to prior authorization or dosage caps, reducing a common barrier to initiating and maintaining treatment.
- Clinicians and treatment programs — face fewer administrative hurdles when initiating or continuing MAT, lowering paperwork, phone calls to payers, and time spent on appeals; this can improve adherence to clinical guidelines.
- Patients seeking long‑acting injectable options — where an injectable exists, States must make at least one such formulation available without PA, expanding access to a modality that some clinicians and patients prefer.
- Public health and correctional health programs — removing PA and dosage caps for at least one option may simplify transitions of care (e.g., discharge from jail or ER) and support higher treatment uptake at a population level.
Who Bears the Cost
- State Medicaid programs — likely face higher pharmacy spend or shifts in utilization as prior authorization and dosage caps are removed for at least one formulation per medication type, forcing budgetary and coverage tradeoffs.
- Medicaid managed care organizations — lose a commonly used utilization‑management lever for covered formulations and must renegotiate provider contracts, change utilization review processes, and absorb operational disruption.
- State legislatures and Medicaid administrators — bear the administrative cost of revising law, rule, and program manuals (and, for some States, will need to pass enabling legislation to comply within the bill’s timeline).
- Federal and state taxpayers — if increased utilization or more expensive formulations (for example, branded long‑acting injectables) drive higher Medicaid spending, government budgets ultimately absorb the increase unless offset elsewhere.
Key Issues
The Core Tension
The central dilemma is straightforward: the bill removes administrative barriers that delay or block evidence‑based opioid treatment—promoting timely access and clinical autonomy—but in doing so it constrains States’ primary tools for containing cost and managing drug safety in Medicaid, creating a tradeoff between expanded access and fiscal and clinical controls with no turnkey solution.
The bill creates a clear policy floor—no PA or dosage caps for at least one formulation per MAT medication type—but key implementation questions remain. The text relies on cross‑references (e.g., to 1905(ee)(1)(A)) rather than defining which specific products or ‘‘types’’ are covered; CMS guidance will be necessary to decide whether a State meets the requirement by covering a single formulation per active ingredient, per mechanism of action, or by other classification.
That definitional ambiguity will matter for manufacturers, payers, and clinicians.
A second tension concerns cost control versus access. Prior authorization and dosage limits are blunt tools used by States and MCOs to control inappropriate use and contain costs; removing those tools for at least one formulation will likely increase utilization of unconstrained options and could shift prescribing toward more expensive products (notably long‑acting injectables).
States may respond by using other legally permissible controls—such as tighter network rules, quantity limits not framed as payment conditions, or stricter clinical monitoring—creating a game of regulatory whack‑a‑mole and potential for litigation over what counts as a prohibited ‘‘limitation on dosage.’'
Finally, enforcement and measurement will challenge CMS and MACPAC. The bill’s reporting requirement aims to illuminate utilization management practices, but MACPAC’s recommendations will depend on access to standardized, comparable data across fee‑for‑service and managed care programs.
Without clear enforcement mechanisms or metrics for compliance, the statutory change could produce uneven access across States and populations, with attendant equity concerns for rural areas and small provider networks.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.